Ryan, Elizabeth

Research focus is the study of Human Dendritic Cell Subsets in different patient cohorts with the goal of manipulating DC therapeutically. Applications for therapy in cancer, chronic viral infection and inflammation. Together with my clinical colleagues I am developing a research programme focusing on immune regulation in the gastrointestinal tract of colorectal cancer and inflammatory bowel disease patients.  A particular interest is the study myeloid lineage cells in human tissue and investigating how they can be perturbed by disease. In addition, we have developed a method to study the immunomodulatory role of the tumour microenvironment of colorectal cancer.

Key publications related to Mye-EUNITER:

McDermott, E; Ryan, EJ; Tosetto, M; Gibson, D; Burrage, J; Keegan, D; Byrne, K; Crowe, E; Sexton, G; Malone, K; Harris, RA; Kellermayer, R; Mill, J; Cullen, G; Doherty, GA; Mulcahy, H; Murphy, TM (2016) 'DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis'. Journal of Crohn's and Colitis, 10 (1):77-86.

Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K (2015) 'Estrogen receptors and their implications in colorectal carcinogenesis'. Frontiers in Oncology, 5.

Gibson, DJ; Elliott, L; McDermott, E; Tosetto, M; Keegan, D; Byrne, K; Martin, ST; Rispens, T; Cullen, G; Mulcahy, HE; Cheifetz, AS; Moss, AC; Robson, SC; Doherty, GA; Ryan, EJ (2015) 'Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease'. Inflammatory Bowel Diseases, 21 (12):2806-2814.

Flood B, Oficjalska K, Laukens D, Fay J, O'Grady A, Caiazza F, Heetun Z, Mills KH, Sheahan K, Ryan EJ, Doherty GA, Kay E, Creagh EM (2015) 'Altered expression of caspases-4 and -5 during inflammatory bowel disease and colorectal cancer: Diagnostic and therapeutic potential'. Clinical and Experimental Immunology.

Caiazza F, Elliott L, Fennelly D, Sheahan K, Doherty GA, Ryan EJ (2015) 'Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies'. Biomarkers in Medicine, 9 (4):363-375.